EV Charging Infrastructure Leader to Implement Operational Cost Reduction Plan Bowie, MD, May 19, 2025 (GLOBE NEWSWIRE) -- Blink Charging Co. (NASDAQ: BLNK) (“Blink” or the “Company”), a leading global owner, operator, provider, and manufacturer of electric vehicle (EV) charging equipment and services, today announced a strategic restructuring plan designed to accelerate its BlinkForward objectives, enhance operational efficiencies, and position the Company for sustained long-term growth and profitability in the evolving global market. The core of this plan includes a difficult but necessary reduction of the Company's global workforce by approximately 20%.

SAN DIEGO , May 19, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Open Lending Corporation (NASDAQ: LPRO) securities between February 24, 2022 and March 31, 2025, inclusive (the "Class Period"), have until Monday, June 30, 2025 to seek appointment as lead plaintiff of the Open Lending class action lawsuit. Captioned Bradley v.

TAMPA, FL, May 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that the U.S. Food and Drug Administration (FDA) has listed U.S. Patent Nos. 11890273 (the ‘273 patent) and 12156869 (the '869 patent), each with an expiration date of October 2041, in its Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) for Arbli™, (losartan …

IRVINE, CA / ACCESS Newswire / May 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, announced the appointment of Jennifer Bright as Chief Financial Officer, effective today, May 19, 2025. Ms. Bright brings more than 25 years of financial and strategic leadership experience built across several commercial-stage medical device and pharmaceutical companies including Biolase, Spectrum Pharmaceuticals, Apria Healthcare, Smile Brands, and Teleflex Medical, as well as technical accounting and auditing experience at PricewaterhouseCoopers LLP.

Theo Trade's Jeff Bierman: “You have to be very careful how you approach this market. I would not rule out a 2009-style flash crash.

PHOENIX--(BUSINESS WIRE)--Western Alliance Bank's subsidiary Digital Disbursements, the leading digital payments platform for the class action legal industry and part of the bank's Juris Banking Group offering, today announced that their Anti-Fraud Triangle innovation, developed in partnership with ClaimScore, a data-driven fraud prevention software solution for class action settlements, has been selected as American Banker's Innovation of the Year in the Cybersecurity and Fraud category. The p.

Jim Wyckoff has spent over 25 years involved with the stock, financial and commodity markets. He was a financial journalist with the FWN newswire service for many years, including stints as a reporter on the rough-and-tumble commodity futures trading floors in Chicago and New York.

During the years of low interest rates and abundant liquidity in the stock market, roughly from 2020 to 2023, a few names were at the top of every investor's watchlist. As it turns out, through every cycle, these names eventually come out of favor when the cycle for credit and money markets swings back around to being more expensive and less available, which throws the same popular names down the list of priorities.

GLDD, EHC and UIS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 19, 2025.

Easily representing one of the hottest investments in the post-pandemic landscape, tech juggernaut Nvidia Corp NVDA stands at a critical crossroads. Mere days away from its first-quarter earnings report, investors will be eager to see how management has negotiated the new economic paradigm under the Trump administration.

ALEX offers a compelling 5.1% yield, backed by a conservative 73% payout ratio and strong fundamentals, which are ideal for income investors. ALEX's strategic asset recycling, robust leasing activity, and low leverage balance sheet support continued growth and resilience. ALEX's focus on needs-based retail and industrial properties in Hawaii, a supply-constrained market, underpins management's raised FFO/share guidance.

PORTLAND, Ore., May 19, 2025 (GLOBE NEWSWIRE) -- LGI Homes is excited to announce the opening of Park Meadow at Walnut Grove, a new section of 30 beautiful, upgraded homes located just down the street from the company's existing community in the desirable Walnut Grove area of Vancouver, Washington.

UnitedHealth's shares have plunged, but the sell-off creates a rare opportunity: the dividend yield is at a historic high and the valuation is compelling. Despite near-term headwinds—guidance withdrawal, CEO change, and reported DOJ probe—I see long-term prospects as strong, with robust earnings and dividend growth expected. UNH's payout ratio is low, and dividend growth history is excellent; even conservative growth assumptions point to attractive total returns for income investors.

STMicroelectronics Announces Status of Common Share Repurchase Program Disclosure of Transactions in Own Shares – Period from May 12, 2025 to May 16, 2025 AMSTERDAM – May 19, 2025 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated June 21, 2024.

BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:

I'm consolidating my BDC holdings into PBDC due to rising risks from prolonged high interest rates and increased competition for quality deals. PBDC offers strong total returns, a nearly 10% dividend yield, and greater income stability compared to individual BDCs, making it attractive for income investors. The ETF's top holdings prioritize first lien senior secured debt, quality underwriting, and portfolio diversity, reducing risk of non-accruals and sector concentration.

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world evidence shows target market for efzofitimod in pulmonary sarcoidosis is higher than previously estimated with increased morbidity.

SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the first patient has been dosed with CX-801 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in the ongoing Phase 1 dose escalation study (NCT06462794) evaluating safety and initial clinical activity in patients with metastatic melanoma.

Investment of $38 million through 2028 at existing Grenada, MS, facility will create more than 450 jobs RACINE, Wis., May 19, 2025 /PRNewswire/ -- Modine (NYSE: MOD), a diversified global leader in thermal management technology and solutions, is investing more than $38 million to expand manufacturing capacity for data center chillers.

16 abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolio TOKYO , May 19, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present 16 abstracts featuring new data across its approved cancer therapies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3). The research underscores Astellas' dedication as a pioneer in oncology and focus on clinical outcomes that matter to patients.